Table 1.
The clinical baseline characteristics of CNSL patients.
| Case | Gender | Age (years) | Diagnosis | FISH | HiSeq deep Sequencing | Site of CNS disease | Systemic disease | Disease status |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 38 | DLBCL IVB; GCB CNS involvement | Negative | KMT2D; CREBBP; GNA13; ID3 | N | N | Chemotherapy refractory then CR after CD19/22 CAR T-cells treatment |
| 2 | M | 55 | Primary CNS DLBCL; non-GCB | TP53 deletion; BCL6 amplification; | MYD88; TBL1XR1; TP53; TMSB4X; IGLL5; SMARCA4 | Left parietal lobe | N | PR |
| 3 | M | 23 | DLBCL IVA; non-GCB | TP53 deletion | NFKBIE; STAT6; TNFAIP3; SOCS1; IGLL5 | Right frontal lobe | N | CNS relapse |
| 4 | F | 35 | DLBCL IVA; GCB CNS involvement | BCL6 rearrangement | NA | Bilateral temporal, occipital, and parietal lobe; callosum | N | CNS relapse |
| 5 | M | 65 | DLBCL IVB; non-GCB | BCL6 amplification | KMT2D; CD79B; MEF2B; TMSB4X | Bilateral paraventricular | N | CNS relapse |
| 6 | F | 39 | Primary CNS DLBCL; non-GCB | NA | NA | Left eye, periocular tissue | N | PR |
| 7 | F | 47 | DLBCL IVA; non-GCB | BCL6 rearrangement | NA | Left cauda hippocampus | Cervical LN | PD (CNS involvement) |
| 8 | F | 32 | DLBCL IVB; non-GCB | BCL6/MYC rearrangement | NA | Left basal ganglia and trigone of lateral ventricle | N | CNS relapse then PD |
| 9 | F | 43 | ILBCL IVB | NA | NOTCH2 | Meninges | N | PD (CNS involvement) then SD |
| 10 | F | 42 | Primary CNS DLBCL; non-GCB | TP53 deletion | TP53; PIM1; ETV6; IRF4 | N | N | Relapse then CR |
| 11 | M | 38 | DLBCL IVA; non-GCB | NA | Negative | Cerebellum vermis and hemispheres | N | CNS relapse |
| 12 | M | 55 | DLBCL IVB; GCB | BCL6 rearrangement | CD70; FAS; DTX1, BCL10; KLF2; RRAGC; CDKN2A, IGLL5; EBF1 | CSF MRD: 7.2% tumor cells | Multiple LN | PD (CNS involvement) |
| 13 | F | 47 | Primary CNS DLBCL; non-GCB | BCL6/MYC amplification | MYD88; TP53 | Right temporal lobe and thalamus | N | Relapse then PR |
M male, F female, CNS central nervous system, GCB germinal center-like B-cell type, DLBCL diffuse large B-cell lymphoma, ILBCL intravascular large B-cell lymphoma, NA not available. FISH fluorescence in situ hybridization, CR complete remission, PR partial remission, SD stable disease, PD progression of disease, MRD minimal residual disease, LN lymph nodes.